Overview

Anumana is an AI-driven health technology company headquartered in Cambridge, Massachusetts, founded in 2021 by nference and Mayo Clinic. It employs an estimated 100-200 people, with an estimated revenue band of $10-50 million, and is privately held. The company develops software that analyzes standard 10-second electrocardiograms to identify early signs of cardiovascular disease, and serves healthcare providers, hospitals, and clinical institutions. Its flagship FDA-cleared product, ECG-AI LEF, detects low ejection fraction, and in March 2026 the company received FDA clearance for an ECG-AI algorithm for early detection of pulmonary hypertension.

At a glance

What Anumana makes

The company holds ISO 13485 certification and offers software that integrates into clinical workflows to convert ECG data into actionable insights.

Certifications

Anumana is associated with the following certifications in public sources. Confirm the certified scope for the specific plant producing your part:

• ISO 13485 — anumana.ai

Latest developments

• 2026-03-28 — Anumana Secures FDA Clearance for First-of-Its-Kind ECG-AI Algorithm for Early Detection of Pulmonary Hypertension - Anumana (anumana.ai)

• 2025-07-17 — Philips Launches ECG AI Marketplace | Philips (philips.com)

• 2025-07-17 — Philips Launches ECG AI Marketplace to Enhance Early Cardiac Diagnosis (anumana.ai)

• 2025-04-24 — Anumana Expands AI Platform from Diagnostic Solutions to the Full Continuum of Cardiovascular Care (anumana.ai)

• 2025-04-24 — Anumana, Inc. announced that it has received funding from Boston Scientific Corporation, Matrix Capital Management, Mayo Clinic, Endowment Arm, Matrix Management Corporation, NTT Venture Capital (anumana.ai)

• 2025-04-24 — Anumana, Boston Scientific collab on AI cardiac care platform (massdevice.com)

Company details

Anumana received funding from Boston Scientific, Matrix Capital Management, Mayo Clinic, and NTT Venture Capital, and in July 2025 its ECG AI was made available through Philips' ECG AI Marketplace. Anumana was founded in 2021, has an estimated 100-200 employees, and is headquartered in Cambridge, Massachusetts. On the LightSource stability read it is rated "Operating": 5 years in operation (founded 2021). Holds ISO 13485 certification(s) per public sources.

Frequently asked questions

What does Anumana make?

Anumana is an AI-driven health technology company headquartered in Cambridge, Massachusetts, founded in 2021 by nference and Mayo Clinic. It employs an estimated 100-200 people, with an estimated revenue band of $10-50 million, and is privately held. The company develops software that analyzes standard 10-second electrocardiograms to identify early signs of cardiovascular disease, and serves healthcare providers, hospitals, and clinical institutions. Its flagship FDA-cleared product, ECG-AI LEF, detects low ejection fraction, and in March 2026 the company received FDA clearance for an ECG-AI algorithm for early detection of pulmonary hypertension.

Where is Anumana headquartered?

Anumana is headquartered in Cambridge, Massachusetts (4 Main St, Cambridge, Massachusetts, 02142-1017).

When was Anumana founded?

Anumana was founded in 2021.

How big is Anumana?

Anumana has an estimated 100-200 employees, with revenue in the $10-50M range (estimated).

What certifications does Anumana hold?

Anumana lists ISO 13485 on its website. Confirm the certified scope for the specific plant producing your part.

Related suppliers

Explore other suppliers in the LightSource directory:

• 10xEngineers

• 1X

• 365 Retail Markets

• 3Com

• 3PAR

Last verified Nov 2026. Is this your company? Request a correction.